Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

NCT00666835 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia

Interventions

DRUG: HX575 epoetin alfa Hexal AG
DRUG: ERYPO®, Janssen-Cilag

Sponsor

Sandoz

Collaborators

[object Object]